Compounds > adibendan
Page last updated: 2024-12-06

adibendan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Adibendan is a synthetic non-steroidal anti-inflammatory drug (NSAID) that was initially developed for the treatment of rheumatoid arthritis. However, it was found to have a high incidence of adverse gastrointestinal effects and was never marketed. Adibendan acts by inhibiting the enzyme cyclooxygenase (COX), which is responsible for the production of prostaglandins, inflammatory mediators that contribute to pain and swelling. It was studied for its potential analgesic and anti-inflammatory properties, but its clinical development was halted due to safety concerns. Further research is ongoing to investigate the potential of adibendan in other therapeutic areas, such as cancer and neurodegenerative diseases.'

adibendan: a pyridyl-pyrrolo-benzimidazole [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65867
CHEMBL ID25931
SCHEMBL ID613156
SCHEMBL ID9832050
MeSH IDM0150286

Synonyms (25)

Synonym
bm-14478
adibendan
CHEMBL25931
7,7-dimethyl-2-pyridin-4-yl-1,5-dihydropyrrolo[2,3-f]benzimidazol-6-one
5,7-dihydro-7,7-dimethyl-2-(4-pyridyl)pyrrolo(2,3-f)benzimidazol-6(3h)-one
100510-33-6
adibendan [inn]
adibendanum
e87n3l27kx ,
pyrrolo(2,3-f)benzimidazol-6(1h)-one, 5,7-dihydro-7,7-dimethyl-2-(4-pyridinyl)-
adibendanum [latin]
unii-e87n3l27kx
adibendan [mart.]
SCHEMBL613156
SCHEMBL9832050
TVLQBBHUNDMTEC-UHFFFAOYSA-N
7,7-dimethyl-6,7-dihydro-2-(pyridin-4-yl)-3h,5h-pyrrolo[2,3-f]benzimidazol-6-one
7,7-dimethyl-2-(4-pyridyl)-6,7-dihydro-3h,5h-pyrrolo[2,3-f]benzimidazol-6-one
bm 14478
DTXSID30143358
7,7-dimethyl-2-(4-pyridyl)-6,7-dihydro-3h,5h-pyrrolo[2,3-f]benzimidazole-6-one
Q15633948
7,7-dimethyl-2-(pyridin-4-yl)-3h,5h,6h,7h-imidazo[4,5-f]indol-6-one
EN300-18567985
AKOS040745489
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID48718Maximum increase in dP/dt when administered intravenously in cats at 0.3 mg/kg dose.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID173456Effective dose required to produce an increase in dP/dt50, blood pressure by 1500 mmHg/s was determined in rat by intravenous administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents.
AID48709Maximum increase in dP/dt recorded in mmHg/s at the dose 0.3 mg/kg administered intravenously in cat1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents.
AID62799Time after which maximum increase in contractility was observed when administered orally in conscious dogs at 1 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID59419Maximum increase in dP/dt when administered intravenously in dogs at 1 mg/kg dose.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID32530Change in calcium-induced activation of canine cardiac myofibrillar ATPase at 200 uM1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
A novel class of cardiotonic agents: synthesis and biological evaluation of 5-substituted 3,6-dihydrothiadiazin-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium sensitizing properties.
AID185708Maximum increase in dP/dt when administered intravenously in rats at 0.1 mg/kg dose.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID59118Effective dose required to produce an increase in dP/dt5 by 1500 mmHg/s in dogs1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID47792Effective dose required to produce an increase in dP/dt5 by 1500 mmHg/s in cats1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID173454Effective dose required to produce an increase in dP/dt5 by 1500 mmHg/s in rats1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID59120Effective dose required to produce an increase in dP/dt50, blood pressure by 1500 mmHg/s was determined in dog by intravenous administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents.
AID185564Maximum increase in dP/dt recorded in mmHg/s at the dose 0.1 mg/kg administered intravenously in rat.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents.
AID59410Maximum increase in dP/dt recorded in mmHg/s at the dose 1.0 mg/kg administered intravenously in dog1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents.
AID58766Amount of time during which increase in administered orally in conscious dogs at 1 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID47794Effective dose required to produce an increase in dP/dt50, blood pressure by 1500 mmHg/s was determined in cat by intravenous administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Nonsteroidal cardiotonics. 1. 2-Pyridyl-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-ones, a novel class of cardiotonic agents.
AID59424Maximum increase in dP/dt60 when administered orally in dogs at dose 1 mg/kg.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
AID219168Inhibition of dog left ventricle sarcoplasmic reticulum bound low-Km c-AMP phosphodiesterase1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
A novel class of cardiotonic agents: synthesis and biological evaluation of 5-substituted 3,6-dihydrothiadiazin-2-ones with cyclic AMP phosphodiesterase inhibiting and myofibrillar calcium sensitizing properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (55.00)18.7374
1990's9 (45.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.55 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-methyl-3-isobutylxanthine
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.		2.38203-isobutyl-1-methylxanthine
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		2.3820catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
milrinone
[no description available]		4.1750bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
pimobendan
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source		8.0750benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
sulmazole
sulmazole: structure given in first source. sulmazole : An imidazopyridine that is 1H-imidazo[4,5-b]pyridine which is substituted at position 2 by a 2-methoxy-4-(methylsulfinyl)phenyl group. An A1 adenosine receptor antagonist, it was formerly used as a cardiotonic agent.		3.7730imidazopyridine;
sulfoxide		adenosine A1 receptor antagonist;
cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		2.3820ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		1.9810azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
dobutamine
Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.		6.9710catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
enoximone
Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.		3.0810aromatic ketone
saterinone
saterinone: structure given in first source		7.3820
mci 154
MCI 154: structure given in UD 38:41n		3.4820
3-amino-6-methyl-5-phenyl-2(1h)-pyridinone
3-amino-6-methyl-5-phenyl-2(1H)-pyridinone: structure given in first source		1.9810
dihydropyridines
Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.		3.0810
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		2.382011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
indolidan
indolidan: structure given in first source		2.3820
tetrodotoxin
Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.		1.9710azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
ici 153110
ICI 153110: structure given in first source		3.0810
beta-escin
[no description available]		1.9710
dihydroouabain
dihydroouabain: RN given refers to (1beta,3beta,5beta,11alpha,20xi)-isomer. dihydroouabain : A cardenolide glycoside that is ouabain in which the double bond in the lactone ring has been reduced to a single bond. It is a cardiac glycoside and a derivative of ouabain which is used as a sodium pump antagonist and exhibits ionotropic effects.		1.9710
r 80122
R 80122: structure given in first source; inhibits cyclic nucleotide phosphodiesterase type III; RN given refers to the E- isomer; R 79595 has no isomeric designation; R 80123 is the Z-isomer		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Cardiac Failure
[description not available]		03.8140
Heart Failure
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.		08.8140
Cardiac Output, Low
A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.		01.9710
Chronic Illness
[description not available]		02.3820
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.3820
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9710